Search Results

Intrinsic Therapeutics, Inc. announced the appointment of Dave Amerson and Tyler Binney to its Board of Directors.

Intrinsic Therapeutics, Inc. announced today that Cigna Healthcare has issued a positive coverage policy for the Barricaid® Bone-Anchored Annular Closure device.

Intrinsic Therapeutics, Inc. today has announced the publication of results from a post-market study that the use of Barricaid in high-risk patients results in significantly fewer reherniations and reoperations when compared to patients treated with discectomy alone.

Kintara Therapeutics, Inc. today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for VAL-083 for the treatment of diffuse intrinsic pontine glioma (DIPG), a rare and highly-aggressive childhood brain cancer.

FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG), a rare, highly aggressive and difficult to treat brain tumor found in children, has been granted Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration (FDA).

Researchers at Children’s Hospital Los Angeles have received a nearly $1 million K08 grant from the National Institutes of Health —as well as funding from the U.S. Department of Defense—to support studies into diffuse intrinsic pontine glioma, a childhood brain tumor with a 0% survival rate.